FST-100 in the Treatment of Acute Viral Conjunctivitis

A Multi-Center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of FST-100 Ophthalmic Suspension in the Treatment of Acute Viral Conjunctivitis

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01461954

Enrollment

132

Registered

2011-10-28

Start date

2013-05-17

Completion date

2014-03-10

Last updated

2021-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Viral Conjunctivitis

Brief summary

This randomized, double masked, multi-center study is being conducted to support the safety and efficacy of FST-100 for the treatment of acute viral conjunctivitis. The study intends to show superiority of FST-100 ophthalmic suspension compared to vehicle for clinical resolution of acute viral conjunctivitis.

Interventions

DRUGFST-100

FST-100

DRUGFST-100 Vehicle

FST-100 Vehicle

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Have a clinical diagnosis of suspected acute viral conjunctivitis in at least one eye

Exclusion criteria

* Have a known sensitivity to any of the components of FST-100 or FST-100 vehicle

Design outcomes

Primary

Measure	Time frame
Clinical resolution of acute viral conjunctivitis	6-7 days

Countries

Brazil, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026